Nearly Half of Surveyed European Retinal Specialists Currently Treat Wet AMD Patients with Bayer's Eylea Eight Months after Its

 Nearly Half of Surveyed European Retinal Specialists Currently Treat Wet AMD
         Patients with Bayer's Eylea Eight Months after Its Approval

Novartis's Lucentis Remains the Most Preferred Intravitreal Pharmacotherapy
for Wet AMD Across the EU5, According to a New Report from BioTrends Research
Group

PR Newswire

EXTON, Pa., Oct. 17, 2013

EXTON, Pa., Oct. 17, 2013 /PRNewswire/ --BioTrends Research Group, one of the
world's leading research and advisory firms for specialized biopharmaceutical
issues, finds that, eight months after the approval of Bayer's Eylea for the
treatment of wet age-related macular degeneration (AMD), nearly half of
surveyed retinal specialists in the EU5 (France, Germany, Italy, Spain and the
United Kingdom) currently treat their wet AMD patients who receive
intravitreal pharmacotherapy (IVT) with Eylea. Retinal specialists report that
Eylea, which boasts a notable dosing advantage over other currently available
IVTs, captures 8 percent patient share among these patients. Data show that
the early uptake of the drug is primarily driven by retinal specialists in
Germany, where the product is significantly more likely to be included on
formularies compared with the other EU5 countries, due to the statutory health
insurance system's obligation to reimburse drugs immediately following
European approval.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The recently published TreatmentTrends: Dry/Wet AMD 2013 (EU) report finds
that, despite the launch of Eylea, physician-reported patient shares for
Roche/Genentech's Avastin and Novartis's Lucentis are unchanged since the
previous year, with Lucentis remaining the patient share leader. In fact,
surveyed retinal specialists continue to rank Lucentis as their most preferred
IVT and their typical first-line choice for wet AMD, which is likely due to
their experience with the drug and their positive perceptions across
efficacy-, safety-, tolerability-, patient benefit- and company
support-related attributes. Nevertheless, patient share for the drug among
IVT-treated wet AMD patients is anticipated to significantly decrease over the
next six months, as is patient share for Avastin. This shift will be
accompanied by significant growth in patient share for Eylea as more retinal
specialists introduce this newer agent into their practices.

Survey findings also reveal that while respondents' awareness and familiarity
with emerging AMD products queried is low, at least 62 percent of respondents
express high interest in learning more about these therapies. More retinal
specialists cite Otsuka/Acucela's ACU-4429 and Alcon's AL-8309B (in
development for dry AMD), as well as Ophthotech's Fovista and Ohr
Pharmaceutical's squalamine (in development for wet AMD) as having the
potential to provide the most value to the treatment of their AMD patients
than any other emerging products.

"The perceived value of ACU-4429 and AL-8309B is driven primarily by the lack
of current treatment options for dry AMD," said BioTrends Research Group
Senior Business Insights Analyst Emma Williams, Ph.D. "In contrast, the value
of Fovista is supported by surveyed retinal specialists' perceptions of its
efficacy, while administration and delivery are the main differentiators of
squalamine, an eye drop. These findings underscore the many opportunities for
new product differentiation that resonate with specialists in this field."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please visit www.bio-trends.com. BioTrends is a
Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group
atwww.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com

SOURCE BioTrends Research Group

Website: http://www.bio-trends.com